A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative, hormone receptor-positive breast cancer and bone metastases

被引：0

作者：

Rugo, H. S.

Drumea, K. C.

Campone, M.

Barnadas, A.

Petrenciuc, O.

Zhang, A.

Li, R.

Coleman, R. E.

机构：

[1] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[2] Rambam Med Ctr, Haifa, Israel

[3] Inst Cancerol Ouest, St Herblain, France

[4] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[5] Bayer HealthCare Pharmaceut, Whippany, NJ USA

[6] Univ Sheffield, Weston Pk Hosp, Sheffield, S Yorkshire, England

来源：

CANCER RESEARCH | 2017年 / 77卷

关键词：

D O I：

10.1158/1538-7445.SABCS16-OT1-04-05

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

OT1-04-05

引用

页数：2

共 50 条

[31] Entinostat, a class Ⅰ selective histone deacetylase inhibitor, plus exemestane for Chinese patients with hormone receptor-positive advanced breast cancer: A multicenter, randomized, double-blind, placebo-controlled, phase 3 trial
Binghe Xu
Qingyuan Zhang
Xichun Hu
Qing Li
Tao Sun
Wei Li
Quchang Ouyang
Jingfen Wang
Zhongsheng Tong
Min Yan
Huiping Li
Xiaohua Zeng
Changping Shan
Xian Wang
Xi Yan
Jian Zhang
Yue Zhang
Jiani Wang
Liang Zhang
Ying Lin
Jifeng Feng
Qianjun Chen
Jian Huang
Lu Zhang
Lisong Yang
Ying Tian
Hongyan Shang
Acta Pharmaceutica Sinica B, 2023, (05) : 2250 - 2258
[32] A phase 2 randomized, double-blind, placebo-controlled multicenter trial evaluating the efficacy and safety of enzalutamide in combination with exemestane in estrogen or progesterone receptor-positive and HER2 non-amplified advanced breast cancer
Yardley, D. A.
Awada, A.
Cortes, J.
Burris, H. A.
Peterson, A.
Bhattacharya, S.
Gianni, L.
Miller, K.
Winer, E.
CANCER RESEARCH, 2013, 73
[33] A Randomized Placebo Controlled Phase II Trial Evaluating Exemestane with or without Enzalutamide in Patients with Hormone Receptor-Positive Breast Cancer
Krop, Ian
Abramson, Vandana
Colleoni, Marco
Traina, Tiffany
Holmes, Frankie
Garcia-Estevez, Laura
Hart, Lowell
Awada, Ahmad
Zamagni, Claudio
Morris, Patrick G.
Schwartzberg, Lee
Chan, Stephen
Gucalp, Ayca
Biganzoli, Laura
Steinberg, Joyce
Sica, Lorenzo
Trudeau, Maureen
Markova, Denka
Tarazi, Jamal
Zhu, Zhou
O'Brien, Thomas
Kelly, Catherine M.
Winer, Eric
Yardley, Denise A.
CLINICAL CANCER RESEARCH, 2020, 26 (23) : 6149 - 6157
[34] Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
Noguchi, Shinzaburo
Masuda, Norikazu
Iwata, Hiroji
Mukai, Hirofumi
Horiguchi, Jun
Puttawibul, Puttisak
Srimuninnimit, Vichien
Tokuda, Yutaka
Kuroi, Katsumasa
Iwase, Hirotaka
Inaji, Hideo
Ohsumi, Shozo
Noh, Woo-Chul
Nakayama, Takahiro
Ohno, Shinji
Rai, Yoshiaki
Park, Byeong-Woo
Panneerselvam, Ashok
El-Hashimy, Mona
Taran, Tetiana
Sahmoud, Tarek
Ito, Yoshinori
BREAST CANCER, 2014, 21 (06) : 703 - 714
[35] Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
Shinzaburo Noguchi
Norikazu Masuda
Hiroji Iwata
Hirofumi Mukai
Jun Horiguchi
Puttisak Puttawibul
Vichien Srimuninnimit
Yutaka Tokuda
Katsumasa Kuroi
Hirotaka Iwase
Hideo Inaji
Shozo Ohsumi
Woo-Chul Noh
Takahiro Nakayama
Shinji Ohno
Yoshiaki Rai
Byeong-Woo Park
Ashok Panneerselvam
Mona El-Hashimy
Tetiana Taran
Tarek Sahmoud
Yoshinori Ito
Breast Cancer, 2014, 21 : 703 - 714
[36] Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial
Smith, Matthew
Parker, Chris
Saad, Fred
Miller, Kurt
Tombal, Bertrand
Ng, Quan Sing
Boegemann, Martin
Matveev, Vsevolod
Piulats, Josep Maria
Zucca, Luis Eduardo
Karyakin, Oleg
Kimura, Go
Matsubara, Nobuaki
Nahas, William Carlos
Nole, Franco
Rosenbaum, Eli
Heidenreich, Axel
Kakehi, Yoshiyuki
Zhang, Amity
Krissel, Heiko
Teufel, Michael
Shen, Junwu
Wagner, Volker
Higano, Celestia
LANCET ONCOLOGY, 2019, 20 (03): : 408 - 419
[37] Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer
Ueno, Naoto T.
Tahara, Rie K.
Fujii, Takeo
Reuben, James M.
Gao, Hui
Saigal, Babita
Lucci, Anthony
Iwase, Toshiaki
Ibrahim, Nuhad K.
Damodaran, Senthil
Shen, Yu
Liu, Diane D.
Hortobagyi, Gabriel N.
Tripathy, Debu
Lim, Bora
Chasen, Beth A.
CANCER MEDICINE, 2020, 9 (03): : 1025 - 1032
[38] Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer The BOLERO-6 Randomized Clinical Trial
Jerusalem, Guy
de Boer, Richard H.
Hurvitz, Sara
Yardley, Denise A.
Kovalenko, Elena
Ejlertsen, Bent
Blau, Sibel
Ozguroglu, Mustafa
Landherr, Laszlo
Ewertz, Marianne
Taran, Tetiana
Fan, Jenna
Noel-Baron, Florence
Louveau, Anne-Laure
Burris, Howard
JAMA ONCOLOGY, 2018, 4 (10) : 1367 - 1374
[39] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
Cantini, Luca
Trapani, Dario
Guidi, Lorenzo
Bielo, Luca Boscolo
Scafetta, Roberta
Koziej, Marcin
Vidal, Laura
Saini, Kamal S.
Curigliano, Giuseppe
CANCER TREATMENT REVIEWS, 2024, 123
[40] EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
K. Almstedt
S. Mendoza
M. Otto
M. J. Battista
J. Steetskamp
A. S. Heimes
S. Krajnak
A. Poplawski
A. Gerhold-Ay
A. Hasenburg
C. Denkert
M. Schmidt
Breast Cancer Research and Treatment, 2020, 182 : 137 - 146

← 1 2 3 4 5 →